AstraZeneca Plc (AZN)

33.64
0.29 0.85
NYSE : Health Technology
Prev Close 33.93
Open 33.53
Day Low/High 33.48 / 33.77
52 Wk Low/High 28.43 / 36.70
Volume 5.54M
Avg Volume 3.54M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 84.99B
EPS 1.20
P/E Ratio 15.22
Div & Yield 1.37 (4.03%)

Latest News

LYNPARZA® (olaparib) Approved By US FDA In Germline BRCA-Mutated Metastatic Breast Cancer

LYNPARZA® (olaparib) Approved By US FDA In Germline BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA ® (olaparib), for use in patients with deleterious or...

US FDA Accepts Regulatory Submission For TAGRISSO (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

US FDA Accepts Regulatory Submission For TAGRISSO (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO ® (osimertinib), a third-generation, irreversible epidermal...

AstraZeneca's CALQUENCE® (acalabrutinib) Shows Potential In Chronic Lymphocytic Leukemia Trials

AstraZeneca's CALQUENCE® (acalabrutinib) Shows Potential In Chronic Lymphocytic Leukemia Trials

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II...

AstraZeneca's CALQUENCE® (acalabrutinib) Demonstrates Activity In Relapsed Or Refractory Mantle Cell Lymphoma Trial

AstraZeneca's CALQUENCE® (acalabrutinib) Demonstrates Activity In Relapsed Or Refractory Mantle Cell Lymphoma Trial

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the...

AstraZeneca To Highlight Its Commitment To Blood Cancers At The 2017 American Society Of Hematology Annual Meeting

AstraZeneca To Highlight Its Commitment To Blood Cancers At The 2017 American Society Of Hematology Annual Meeting

AstraZeneca, along with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer...

Celebrity Trainer And Author Bob Harper Teams Up With AstraZeneca To Connect With Fellow Heart Attack Survivors

Celebrity Trainer And Author Bob Harper Teams Up With AstraZeneca To Connect With Fellow Heart Attack Survivors

Bob Harper, celebrity personal trainer, author and heart attack survivor, is teaming up with AstraZeneca to help people like him who have experienced a heart attack share their stories to educate and inspire others.

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche sees success in trials for its cancer and hemophilia drugs

FASLODEX® (fulvestrant) Receives US FDA Approval For The Treatment Of Advanced Breast Cancer In Combination With Abemaciclib

FASLODEX® (fulvestrant) Receives US FDA Approval For The Treatment Of Advanced Breast Cancer In Combination With Abemaciclib

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication for FASLODEX ® (fulvestrant), expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for...

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

Surviving the age of Amazon is all there is to retailers' earnings.

AstraZeneca Stock Gains as Crestor Sales Decline Slows

AstraZeneca Stock Gains as Crestor Sales Decline Slows

Sales in China picked up as decline in Crestor revenue slowed.

AstraZeneca Shares Scientific Updates From Its Extensive Cardiovascular, Renal And Metabolic Diseases (CVMD) Portfolio At AHA 2017

AstraZeneca Shares Scientific Updates From Its Extensive Cardiovascular, Renal And Metabolic Diseases (CVMD) Portfolio At AHA 2017

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two...

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug

With newly approved Calquence in hand, AstraZenca is set to compete against J&J-AbbVie's Inbruvica first on mantle cell lymphoma but down the road the challenge could be on more common blood cancers.

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Powerhouse performances from Caterpillar and 3M inspire a Dow rally, leading the index to new all-time highs in its 54th record close of the year.

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Better-than-expected earnings from a number of key Dow components sweep markets higher.

(Photo: Business Wire)

(Photo: Business Wire)

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON ® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON ® (exenatide...

AstraZeneca Announces New Data Showing US Preterm Infants At Significantly Greater Risk Of RSV Hospitalizations Following 2014 Guidance Change

AstraZeneca Announces New Data Showing US Preterm Infants At Significantly Greater Risk Of RSV Hospitalizations Following 2014 Guidance Change

AstraZeneca today announced new results of a study that investigated respiratory syncytial virus (RSV) hospitalization risk and costs during the 2014-2016 RSV seasons compared to the 2012-2014 RSV seasons.

US FDA Accepts Supplemental Biologics License Application For IMFINZI® (durvalumab) In Locally Advanced, Unresectable Non-Small Cell Lung Cancer

US FDA Accepts Supplemental Biologics License Application For IMFINZI® (durvalumab) In Locally Advanced, Unresectable Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for IMFINZI ® ...

Flexion's Latest FDA Approval Reignites Takeover Chatter

Flexion's Latest FDA Approval Reignites Takeover Chatter

The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation By US FDA For The 1st-Line Treatment Of Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation By US FDA For The 1st-Line Treatment Of Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for TAGRISSO ® (osimertinib) for the 1st-line treatment of patients with metastatic...

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.

Markets Move Higher; Inversion Rules Put Pfizer-Allergan Back In Focus -- ICYMI

Markets Move Higher; Inversion Rules Put Pfizer-Allergan Back In Focus -- ICYMI

Here's what you need to know now for Monday, Oct. 2.

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Newly public companies such as Roku, NuCana and Restoration Robotics could bring a jolt to your portfolio. But remember all IPOs aren't created equally.

CEOs Are Dropping Like Flies

CEOs Are Dropping Like Flies

So far in 2017, we have had to say farewell to many CEOs, including these.

Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile And Fewer CV Events In Patients With Type-2 Diabetes At Wide Range Of CV Risk

Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile And Fewer CV Events In Patients With Type-2 Diabetes At Wide Range Of CV Risk

AstraZeneca today announced full results from the EXSCEL ( EX enatide S tudy of C ardiovascular E vent L owering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in...

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

Wall Street starts the week with a rally.

TheStreet Quant Rating: B- (Buy)